Hebbian Bio

PhD scientists often don’t get to see the patients who are affected by the conditions they study. It has been transformative to regularly meet and interact with patients and their families for us. We had the privilege to take part in this year’s Project 8p Foundation science conference and spend time with 8p heros and their families over breakfast, lunch, dinner, and dancing, and we learned so much 💫🙏🏼 Project 8p Foundation is a pioneer on many fronts, including their openness to novel technologies. Thank you for being our 1st pilot partner in utilizing Hebbian Bio’s neuroprecision platform for drug #target and #biomarker discovery #precisionpsychiatry #neurodevelopmentaldisorders #autism #schizophrenia #adhd #raredisease #neuro #CNS #precisionhealth #precisionmedicine

It was a privilege to attend the 2024 Precision Health Summit together with a group of leaders in the #precision health and medicine space, last week in NYC. Key takeaways: 💡in the past year, 38% of all FDA-approved drugs were precision medicine, utilizing biomarkers 💡2/3 of all drugs in pharma-driven clinical trials are categorized as precision medicine Precision medicine as an approach is clearly working in cancer and is here to stay. At Hebbian Bio, we are focused on neuro conditions by building a neuro-precision platform for better drug target identification and patient stratification. Much of our work is centered on neurodevelopmental disorders, some of which are currently classified as #rare, a concept that will be obsolete as precision medicine advances. Hebbian Bio is making “rare” less rare.

📢 Connect with WCBA alum in person next Wednesday! We're thrilled to invite you to an engaging panel discussion led by FirstXFounder Alums. This event is a unique opportunity to dive deep into the 2025 WCBA application process and connect directly with the WCBA program team. 🔗 - https://lu.ma/frrii3r8 🗓️ Date & Time: August 28, 6 - 7:30 PM 📍 Location: Mortimer B. Zuckerman Research Center Why you should attend: 💡 Gain insights from FXF Alums and experiences #entrepreneurs 💡 Learn key details about the 2025 WCBA application process 💡 Connect in-person with the WCBA program team and get your questions answered! The WCBA program supports academic and corporate spinouts, inventors, and first-time founders in building emergent ventures. Don’t miss this chance to network and learn from the best in the industry. 🤝 Co-hosted by: The Tri-Institutional Startup Venture Group, TRIBC, and BiotechXYZ Speakers: Hourinaz Behesti, Founder: Hebbian Bio Paul Booth, Applied Surgical Robotics Prakrit Jena, Lime Therapeutics 👥 Shoutout to: Nick Bartello, Margaret Hoang, Thasin Peyear, Raquel Castromonte, Annalisa Ferrotta Join us and take a significant step towards your entrepreneurial journey! 🌟 #Biotech #WCBA2025 #Startup #Innovation #Networking

This was the best way to get started! We are grateful for all the learnings, opportunities, and the community that helped accelerate our path in pursuing our mission to bring first-in-class treatments for #neurodevelopmental conditions #nycbiotech #neuroprecision

It’s Patient Advocacy Group conference season! We recently took part in the CACNA1A Foundation patient and scientist research round table at the National Institute of Neurological Disorders and Stroke (NINDS). We learned so much from spending time with the patients. Lots of cool new initiatives on how to better quantify movement, speech, and overall progression to help find the right treatment for the right patient. “A key takeaway was that to achieve our mission of finding better treatments and a cure for CACNA1A-related disorders, we must continue the strong partnership between the families, the CACNA1A Foundation, and the Research Network. Families provide the information and tools to understand our disease. Researchers utilize these assets to develop and test treatments. And, the Foundation bridges these two communities, supporting and holding them together to move forward” 💯

Primetime for #neuropsychiatric symptoms: “The Lancet Psychiatry forecasts that 1/2 of the global population will experience a mental health disorder in their lifetime. Yet current treatments fall short for up to 1/3 of the patients. There are two paths ahead for innovation: design better drugs for established targets or find entirely new biological mechanisms” Hebbian Bio is doing the latter. Our focus is on #neurodevelopmentalDisorders 💡The global mental health treatment market is expected to exceed $500 B by 2028.

See you there NYC #startup #nycbiotech #precisionCNS

ONLY 48 HOURS AWAY: The 12th Annual WCBA & ABCT Pitch Day in Midtown Manhattan! Get your tickets today: https://lnkd.in/gdWPVsSQ Learn more about first-time founders who will share their groundbreaking solutions during Pitch Day: WCBA: Westchester County Biosciences Accelerator (The Catalyst) Anita Lee - Twin Weavers Ariel Y. (Ariel Yusupov), New York Medical College, FIG Therapeutics, Inc. Inc Daniel S. Gareau, The Rockefeller University, SurgiVance Inc Evris Gavathiotis, Albert Einstein College of Medicine, BaxGen Therapeutics Glen Prusky, Weill Cornell Medicine, Gaze Engine Hourinaz Behesti, Rockefeller University, Hebbian Bio Ilya Popov, MBA, Independent, ComeBack Mobility Dr. Katia M. R. (Katia Rojas), Independent, Suabix Kirsten Hund Blair and Kevin McClarren, Independent, Lambent Data, Inc. Zach S. (Zach Sawaged), Independent, Concordare ABCT: Accelerator for Biosciences in Connecticut Courtney K Rowe, MD, Christopher Foster, and Kelly Burke, University of Connecticut, Pallivex Joshua Gilmore, Independent, Social Health Passport Julien Berro and Yuan Ren, Yale University, Nanochuk Ming Hui, Indepedent, Mobabbi Prisca Obi, Yale University, Virtus Therapeutics Vanessa Sena and Helen Wu, Independent, My Local Chefs

We are thrilled to be one of 16 ventures pitching at the FirstXFounder’s 2024 WCBA: Westchester County Biosciences Accelerator (The Catalyst) & ABCT: Accelerator for Biosciences in Connecticut Pitch Day on May 9th in New York City. Use the code “FULLCOMP24” for a complimentary ticket and come learn more about our platform technology for tackling neurodevelopmental disorders. #CNS #NYCbiotech #raredisease #autism #investmentopportunity #impactinvesting #startup https://lnkd.in/egkAFVTA

We will be at the World Orphan Drug Congress USA, in Boston next week. Reach out to connect and learn about our precision target and biomarker discovery platform for rare CNS disorders and how we can partner #HebbianBio #raredisease #precisionMedicine #CNS